Trial ID or NCT#

NCT01467479

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA) 12 weeks after the last planned dose of study drug.

Official Title

An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1)

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Philip Grant
Philip Grant
Positive care doctor, Infectious disease doctor
Assistant Professor of Medicine (Infectious Diseases) at the Stanford University Medical Center
Andrew Zolopa

Contact us to find out if this trial is right for you.

CONTACT

Debbie Slamowitz
(650) 723-2804